Surrogate endpoints with Huseyin Naci

This week, we’re joined by Huseyin Naci to discuss the recent press release from Eisai and Biogen announcing the Phase III trial results for lecanemab for use in Alzheimer’s disease, and the FDA’s decision to accept the drug onto its accelerated approval pathway. We talk about the pros and cons of using surrogate endpoints to predict clinical outcomes. How can we strike a better balance in clinical trials between generating high-quality and trustworthy evidence, and the urgent needs of patients with life-limiting conditions and very few available treatment options? Our guest: Huseyin Naci is an associate professor of Health Policy at the London School of Economics and Political Science (LSE). He is also an advisor to the Analysis section of The BMJ.

You can listen to Surrogate endpoints with Huseyin Naci online on Radio and Podcast. Open the player on this page to stream the available audio.

Surrogate endpoints with Huseyin Naci is an episode from Deep Breath In by The BMJ.

This episode is 47:13 long.

This episode was published on Nov 11, 2022.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Deep Breath In when more episodes are available from the podcast feed.